Heterogeneity of phenotype in two cystic fibrosis patients homozygous for the CFTR exon 11 mutation G551D

Richard B Parad

Abstract
In the heterozygous state, the cystic fibrosis transmembrane conductance regulator (CFTR) exon 11 mutation G551D has been described as "severe," causing pancreatic insufficiency. Two cystic fibrosis (CF) patients homozygous for this mutation showed a mild rather than severe pancreatic phenotype and a variable pulmonary phenotype.

(J Med Genet 1996;33:711-713)

Key words: cystic fibrosis; CFTR exon 11; G551D.

CF has been associated with over 500 mutations in the CFTR gene. The most common mutation, AF508, accounts for approximately 70% of CF alleles. G551D, an exon 11 mutation in the first nucleotide binding fold (NBF) of the CFTR protein, is one of the most common non-AF508 mutations, occurring at a world wide frequency of 3%. The influence of CFTR genotype on CF phenotype is poorly understood. Availability of only small numbers of patients homozygous for rare genotypes makes it difficult to accumulate enough clinical data to attempt phenotype correlation. Reported here are the clinical courses of two patients homozygous for CFTR mutation G551D. Potential pitfalls of using data available from heterozygotes to predict phenotype in homozygotes are illustrated.

Methods
Cheekbrush DNA for CFTR mutation analysis was collected and prepared according to Richards et al.1 CFTR mutation analysis was performed for 12 mutations (AF508, G551D, G542X, 621+1G→T, Δ507T, 1717-1G→A, R117H, N1303K, W1282X, R560T, R553X, 3849 + 10kb C→T). Genotyping for all CFTR mutations, except for 3849 + 10kb C→T, which was assessed by restriction enzyme digestion with HphI,2 were evaluated by the Multiplex Amplification Refractory Mutation System (ARMS).3 The reaction volumes were modified from the Ferriero protocol to incorporate 20 μl of buccal cell DNA into the PCR reaction mixture. DNA from patient 1 was also assessed for 12 mutations by allele specific oligonucleotide analysis (ASO),4 but S549N was screened in addition, and 3849 + 10kb was excluded.

Case reports
Case 1
This patient was a white female diagnosed with CF at the age of 6, with a history of recurrent pneumonia and no malabsorption or gastrointestinal symptoms. Family history was positive for CF in a maternal cousin. All grandparents were from Ireland, although there was no history of consanguinity. Quantitative pilocarpine iotophoresis at diagnosis showed a sweat chloride value of 107 mEq/l. She was subsequently admitted to hospital two to three times a year for pulmonary exacerbations. She developed steroid dependent reactive airway disease. Her sputum grew mucoid Pseudomonas aeruginosa before the age of 12. By the age of 15, percent predicted forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) were 50%. When pancreatic enzyme supplementation was started at the age of 16 (owing to low vitamin A level), height and weight were at the 50th centile for age. There was no liver disease or diabetes mellitus (DM).

In her mid teens she developed mild haemoptysis and gradually declining pulmonary function with increasing frequency of admission to hospital for pulmonary exacerbations. Chest radiograph and chest computed tomography showed bronchiectasis. By the age of 19 she required night time oxygen supplementation and developed CO2 retention. She died at the age of 20 of progressive respiratory failure.

Case 2
This patient was first diagnosed with CF at the age of 36 with complaints of chronic bronchitis and asthma. Although always short and thin (height and weight at the 5th-10th centile), he had no malabsorption stools or GI symptoms until the age of 15. At that time, he was admitted to hospital for a transient bowel obstruction which was successfully treated by enema. There was no liver disease or DM. Chronic cough was present from infancy. Although he complained of exertional dyspnoea as a child, asthma was not diagnosed until the age of 17. Treatment included inhaled steroids and bronchodilators. There was no documented pneumonia and no admissions to hospital for respiratory problems. An infertility evaluation at the age of 33 showed azoospermia. His first episode of mild haemoptysis occurred at the age of 34 after a sudden coughing paroxysm. The CXR, which had been previously reported as unremarkable, had changed to a granular nodular pattern with peribronchial thickening. A diagnosis of sarcoidosis was considered, and
Thoracoscopy biopsy indicated an inflammatory non-granulomatous process and bronchitis. Because the diagnosis of CF was included in the differential diagnosis, a quantitative pilocarpine iontophoresis was performed and showed a sweat chloride of 101 mEq/L. Sputum grew *Staphylococcus aureus* and rare non-mucoid *Pseudomonas aeruginosa*. Following a first course of intravenous antibiotics, post-bronchodilator FVC was 98%, FEV1, 70%, and forced expiratory flow from 25 to 75% of vital capacity (FEF25-75) 28%. Vitamin A and E levels, prothrombin, and partial thromboplastin time and 72 hour stool fat collection were normal. Family history was negative for CF, and there was no known consanguinity.

**Results**

Fig 1 shows the multiplex ARMS reaction for assessment of mutations ΔF508, G542X, G551D, and 621 + 1G→T. The pair of lanes labelled 1 was performed on a known heterozygote for mutation G551D. The pair of lanes labelled 2 was performed on a non-CF control to illustrate a normal pattern. DNA from patient 1 showed a single band in the mutant lane for mutation G551D in the lanes under 3. This result was confirmed by ASO analysis (data not shown). The lanes under 4 show the same pattern seen in patient 2. All other mutations tested for were absent.

**Discussion**

The CFTR missense mutation G551D is a Gly to Asp substitution at amino acid position 551 that results from a G to A substitution at the cDNA base pair numbered 1784 in exon 11. This glycine is a highly conserved amino acid in the first nucleotide binding fold of the CFTR protein.

The allele frequency of G551D in CF patients from Europe has been documented in a north west to south east gradient, the highest frequency reported in Northern Ireland (8.3%) and less than 0.1% found in southern European/Mediterranean populations. In the USA, the frequency varies from 1 to 4%.

Clinical utility would be derived from being able to anticipate CF disease severity given a patient's genotype. Rationalisations of how mutations could result in different severity of disease have been based on a number of schemes, including region of protein affected (NBF v transmembrane or regulatory domains), cellular function disrupted (protein production (category I) v processing (category II) v regulation (category III) v conduction (category IV)), or type of mutation (for example, missense v frameshift or splice mutations). Genotype-phenotype correlations have been in closest agreement between pancreatic phenotype and specific mutations. Consistent pulmonary phenotype has only been suggested with two mutations, R117H and A455E.

G551D has been characterised as a class III mutation through its presumed impact on ATP binding. Recent studies have shown present (but diminished) chloride conductance, and absent CFTR inhibitory regulation of the outwardly rectifying chloride channel. Organ specific phenotypes associated with individual CFTR mutations may in part be dependent on what back up systems are available for the disrupted CFTR function within the cells populating that organ.

G551D was originally categorised as a "severe" mutation with respect to pancreatic insufficiency (PI). All 21 ΔF508/G551D heterozygotes, five compound heterozygotes for G551D and other non-ΔF508 mutations, and one G551D homozygote fit criteria for PI. "Severe" pancreatic alleles were also proposed to be recessive to "mild" pancreatic sufficient (PS) alleles, suggesting that a patient homozygous for a "severe" allele should present early symptoms of PI. In a retrospective cohort study by Hamash et al. of 79 AF508/G551D compound heterozygotes, no significant clinical differences from AF508 homozygotes could be detected, with the exception of a lower risk for meconium ileus (MI) in the AF508/G551D heterozygotes at birth. Of the other outcome parameters assessed, only the age at PI tended towards a later age in the compound heterozygotes (1.9 ± 2.8 v 2.7 ± 4.0 years). Three G551D homozygotes were alluded to in that report, and they were briefly described with minimal detail as PI with no history of MI. A conflicting report by Curtis et al. documented three pancreatic sufficient G551D compound heterozygotes. Discrepancies in designation of compound heterozygotes as PS rather than mild PI could be based on differences in methods or criteria used for documenting that diagnosis.

For the two cases presented, phenotypic similarities include the relatively mild pancreatic (late mild PI in patient 1 compared to PS in patient 2) and mild intestinal phenotypes (no MI in the newborn period for either, and late meconium ileus equivalent in patient 2) and presentation with mainly respiratory symptoms (although one was mild and the other severe). The ages of diagnosis and age at PI in patients 1 and 2 are much older than the means proposed for ΔF508/G551D heterozygotes (table 1). The disparity in severity of respiratory disease of these patients could be related to the absence of mucoid *Pseudomonas aeruginosa* (an organism known to be associ-

**Figure 1** Ethidium bromide stained agarose gel showing PCR products of the multiplex ARMS protocol. Lanes are paired to show both normal and abnormal alleles containing mutations 621 + 1G→T (normal band lane 1, abnormal band lane 2), G551D (abnormal band lane 1, normal band lane 2), G542X (abnormal band lane 1, normal band lane 2), and ΔF508 (normal band lane 1, abnormal band lane 2) at these loci. The first pair of lanes shows the ARMS pattern of a G551D heterozygote. The band pattern of a normal subject (N/N) at these four loci is shown in the second pair of lanes. The third and fourth pairs of lanes were generated using DNA from patients 1 and 2 (G551D/G551D).
Table 1  Clinical characteristics: comparison between reported homozygotes for G551D and previously published heterozygous and homozygous series

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Ref</th>
<th>No of patients</th>
<th>Age at diagnosis (y)*</th>
<th>No with PI†</th>
<th>Age at PI (y)*</th>
<th>No with MI‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heterozygotes</td>
<td>G551D/AF508</td>
<td>5</td>
<td>79</td>
<td>1.9 (2.8)</td>
<td>79</td>
<td>2.7 (4.0)</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>21</td>
<td>NR</td>
<td>21</td>
<td>NR</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>13</td>
<td>5</td>
<td>NR</td>
<td>5</td>
<td>NR</td>
<td>1</td>
</tr>
<tr>
<td>Homozygotes</td>
<td>G551D/other</td>
<td>12</td>
<td>3</td>
<td>NR</td>
<td>0</td>
<td>NR</td>
</tr>
<tr>
<td>G551D/G551D</td>
<td>5</td>
<td>1</td>
<td>NR</td>
<td>1</td>
<td>NR</td>
<td>0</td>
</tr>
<tr>
<td>Patient 1</td>
<td>12</td>
<td>3</td>
<td>NR</td>
<td>3</td>
<td>NR</td>
<td>0</td>
</tr>
<tr>
<td>Patient 2</td>
<td>5</td>
<td>6</td>
<td>NR</td>
<td>1</td>
<td>NR</td>
<td>0</td>
</tr>
<tr>
<td>R</td>
<td>12</td>
<td>3</td>
<td>NR</td>
<td>1</td>
<td>0</td>
<td>NA</td>
</tr>
</tbody>
</table>

* Mean (SD).
† Pancreatic insufficiency.
‡ Meconium ileus.
NR, not reported.
NA, not applicable.

This study was supported in part by NIH grant DK2273 and by a Trudeau Scholarship of the American Lung Association.

References:
12. Fulmer SB, Schwiebers EM, Morales MM, Gugino WB, Cutting GR. Two CFTR mutations have different effects on both pulmonary phenotype and regulation of outwardly rectified chloride currents. Pediatr Pulmonol 1995;suppl 12:182A.
Heterogeneity of phenotype in two cystic fibrosis patients homozygous for the CFTR exon 11 mutation G551D.

R B Parad

*J Med Genet* 1996 33: 711-713
doi: 10.1136/jmg.33.8.711

Updated information and services can be found at:
http://jmg.bmj.com/content/33/8/711

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/